acmefirewoodis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It doesn't.
There's a difference between failure to file and being a day or two late.
Old adage: "Fool me once shame on you. Fool me twice shame on me."
What has the old C.F.O. been doing the last three and a half months?
As C.E.O. and Chairman of the Board doesn't Gerald have the responsibility to the shareholders to see that the filings are done on time?
Just saying!!!
p.s. How about a new Chairman of the Board? Possibly Gerald is in over his head?
I spoke with Russell about thirty minutes ago. I think the 10-K was filed because during the course of our conversation he was actually accessing the S.E.C. website. The only reason he would do that would be to see if it had been published there before confirming it had been filed.
He asked me to send him an e-mail and that he would get back to me when he found out something.
"Patience is a virtue."
Let's hope that the "Peter Principle" is not alive and well at Amarantus.
With the importance attached to meeting the filing deadline I can't imagine that Gerald would miss it.
As I stated before until it is missed I will assume that it won't be.
Tick Tock!!!
p.s. As someone just pointed out to me possibly Gerald should spend less time "tweeting" and more time focused on getting the 10-K completed on time.
If the 10-K isn't filed today I think you'll be able to get shares for a nickle tomorrow.
Dominion has a lot of .03 shares to sell.
Just saying!!!
p.s. Evidently Gerald's kitchen is getting rather empty.
Note: The delay in filing the 10-K doesn't offer much support for Gerald's statement about building a "world class company". Old adage says, "Actions speak louder than words".
On the bright side if the 10-K isn't filed by the open tomorrow it's almost a certainty that the share price will be below .07 as it barely held .07 today.
There's also the possibility that even if the 10-K is filed before the open tomorrow that depending on its contents the share price could still go below .07 if there is no other news.
In either case the opportunity will be there to buy cheaper shares if one chooses to do so.
p.s. The most recent low was .063.
It was Gerald who stated that he is building a "world class company".
Until the deadline is missed I will assume that it won't be.
Just saying!!!
If they miss the deadline I expect the share price will go below .06.
How difficult can it be to create a 10-K with three and a half months to do so?
Just saying!!!
p.s. World class companies don't miss filing deadlines.
Another "DTC chill order" would kill the share price. Back to .03.
Let's get the 10-K filed.
Just saying!!!
p.s. Nine employees now and a new C.F.O. and the 10-K can't be filed when due?
Didn't you read Napadano's last article? The 800+ million shares is already priced in his .24 valuation.
Still expecting a double/triple within 90 days.
Twitter: @AmarantusBio .... 9,896 followers.
Considering all the steps that Gerald is taking to assemble the team to make Amarantus a "world class company" how can anyone not believe that it's only a matter of time before the share price moves substantially higher and continues on an uptrend.
I still think one p.r. could move the share more in line with Jason Napadano's current valuation of .24.
Twitter: @AmarantusBio .... 9,891 followers
Should surpass 10,000 this week.
Note: Remember to "retweet" the company's tweets to your followers.
It appears Gerald wants to end the negative speculation.
Gerald Commissiong ?@G_Commish 2h
Dr. Saarma recent Cell publication is excellent, and confirms Dr. Urano's original work. Reproducibility is the hallmark of good science.
Gerald Commissiong ?@G_Commish 2h
Unfortunately for our detractors, science doesn't care about the share price. We are very excited about our current position and our future.
Gerald Commissiong ?@G_Commish 3h
Amarantus owns comp. of matter patents for MANF and certain use patent apps. We have also licensed certain use apps for MANF and CDNF.
Gerald Commissiong ?@G_Commish 3h
Dr. Saarma is excellent scientist. We have great appreciation for his work. MANF field emerging in cell biology. Dr. Saarma is a KOL on MANF
Gerald Commissiong ?@G_Commish 3h
Dr. Saarma challenged validity of broad scope of AMBS MANF patents in Europe in 2012. European Commission sided 100% with Amarantus. Period.
Gerald Commissiong ?@G_Commish 3h
MANF is not MANF2. Dr. Saarma discovered MANF2 after Dr. Commissiong discovered MANF. Dr. Saarma changed name of MANF2 to CDNF. MANF2 = CDNF
Gerald Commissiong ?@G_Commish 3h
Dr. Urano's application precedes Dr. Saarma's, and will represent prior art. Amarantus controls MANF indication in beta cell disorders.
Gerald Commissiong ?@G_Commish 3h
Amarantus is now paying for prosecution per our agreement with UMass and we will enter the nationalisation phase shortly.
Gerald Commissiong ?@G_Commish 3h
These patents have already published (1.5 year provisional, 1 year PCT) and Amarantus licensed them in December 2013.
Gerald Commissiong ?@G_Commish 3h
For clarity, there is no ambiguity: @FumihikoUrano conceived, reduced to practice, and filed patents for MANF beta cell indications in 2012
Retweeted by Gerald Commissiong
Zoomboom ?@zoneblitzzzz Apr 11
@biostockwatcher @JNapodano @G_Commish @FumihikoUrano Dr Urano has the Patent filed 1st for this as the original inventor.
I'm still expecting the one p.r. that doubles or triples the share price and takes it much closer to Napadano's .24 valuation.
Not if but when.
Twitter: @AmarantusBio .... 9,889 followers.
p.s. I'll take Novartis and you can have the field.
Novartis.
p.s. No speculation here.
Twitter: @AmarantusBio ....9,884 followers.
Note: Remember to "retweet" the company's tweets to your followers.
Substantially oversold. Company has no debt.
Mid $30's next week.
"In Gerald we trust."
I think that pretty much sums up why the majority of AMBS shareholders are buying and holding shares for the long term.
Twitter: @AmarantusBio .... 9,880 followers
If you believe in Gerald the current price is a gift. If you don't then you shouldn't own shares in the company.
I'm still thinking this is one press release from the share price doubling or tripling and the up-listing being announced.
"Patience is a virtue."
Twitter: @AmarantusBio .... 9,880 followers.
Jason Napadano placed a valuation of .24/share when there was 385,000,000 shares outstanding and now he places a value of .24/share with 800,000,000 shares outstanding at some point.
If I have to explain to you why that is a positive then I might suggest that you're in over your head.
It might interest you to note that his price target is about three times the current share price. Imagine if it only doubles over the next six to eight months or by next week. I'd say that a pretty good return.
If you want someone to represent the company in a pissing contest about the company's achievements to date and the company's future who better to do so than Gerald.
Just saying!!!
Wall Street Daily ?@wallstreetdaily
@JNapodano Jason, I wanted to thank you for your SA Article on $AMBS. I found it quite informative.
Jason Napodano, CFA ?@JNapodano 4h
@wallstreetdaily You're welcome! I'll be working up a new one in the not-too-distance future. Just waiting for their 10K filing.
As Paul Harvey used to say, "Stay tuned for news."
Nine employees, a group of world class advisers, and $30,000,000 in cash available over the next thirty months.
Gerald has the means to implement his plan.
I have to believe that it's still only one p.r. away from doubling/tripling the share price at any time. Up-listing?
Twitter: @AmarantusBio .... 9,877 followers. Remember to "retweet" the company's tweets.
Note: Expecting another article from Jason Napadano soon.
The company has over $30,000,000 to "burn" over the next thirty months.
Let's see what significant news results during that time frame.
Just saying!!!
p.s. You say "burn" and I'll say "invest".
Until the F.D.A. issues its decision and the market knows the requirements placed on Afrezza such as REMS, pulmonary lung function testing, and cancer warning or cancer studies it's impossible to have a glimpse of Mannkind's future.
If the F.D.A. requires patients to have a lung function test to establish a baseline before Afrezza is used along with a follow-up test in six months that would add another $300 to $600 cost to using the drug. Is a type 2 diabetic likely to switch from a pill to an inhaled drug? I think not.
The "terms" of the decision will likely determine if Mannkind is able to find a "big pharma" partner to market Afrezza. Failure to do would necessitate that Mannkind raise another $300M to market Afrezza "in house".
Also of interest is GSK having their once a week insulin expected to be approved on April 15.
I think with over 425M shares on a fully diluted basis that a fair value for Mannkind is currently in the $3.50 range to be adjusted in July once the F.D.A. places the restrictions on Afrezza.
My days speculating about what may and may not happen with AMBS are behind me. I'll read the news released by Gerald and try to determine if it warrants buying or selling shares. I'm evolving into a pragmatist.
Let's hope there is some positive news to accompany the release of the delayed 10-K otherwise I think a much lower share price lies ahead.
GLTA
On a fully diluted basis it's probably in the 830,000,000 range currently although a higher figure wouldn't surprise me.
We'll know soon enough.
If you think it's substantially lower then act accordingly. I have no control over whether you chose to buy, sell, or hold.
As I've always said it would only take one p.r. to double or triple the share price and that could occur ay any time.
No deception here. Based on past trading patterns if the 10-K discloses additional dilution beyond what has been disclosed the share price will go lower if there is no news to offset it.
Posting this belief is not deceptive at all. I think the share price could drop to the .063 range. I doubt if it will go lower.
If it happens so be it. If it doesn't happen so be it.
Even though I probably own more shares than all but a handful of individuals posting here I'm still posting what I believe will occur soon even if it is viewed as being negative. If I'm wrong then it will be obvious.
Have a great day!!!
p.s. I have Florida versus Wisconsin in the finals but Kentucky versus UConn could be an interesting turn of events.
Who would you say is dumber?
Someone who bought shares below .03 and didn't sell any when the share price was above .12 or someone who bought shares above .12 thinking it was going higher?
Just asking.
So you think that someone who bought at .14 is a bagholder. Very interesting belief.
How high can someone have purchased shares and not be considered a bagholder?
LOL!!! You're so funny.
p.s. Are you adding more shares below .07?
Contact the company and have them update the website to correct their mistake. I'm certain you know more than they do.
http://biz.yahoo.com/e/130426/ambs10-k_a.html
What is the date on this document?
http://ir.stockpr.com/amarantus/all-sec-filings?page=5#document-7984-0001255294-13-000296
p.s. Isn't it great to learn new things?
Last year they filed it on 4/26. The late filing was partially responsible for the D.T.C. "chill" order that went into effect for 90 days.
Hopefully Gerald learned his lesson.
I think it will hit .07 tomorrow not .05.
After the 10-K is issued I think you'll get shares in the .065-.07 range if there is no new news.
"Patience is a virtue."
They're never gone. They are on loan for a few days.
Depending when the 10-K is issued and barring any positive news I think I'll get them back at a substantial discount.
Watch and learn.
p.s. I don't think it will go below .065.
Note: I've been wrong before.
Hopefully the 10-K will be out soon. It's often said that the "devil is in the details".
I'm anxious to see how bad the dilution actually might be on a "fully diluted basis".
Any positive news would help to offset my expectations.
Why won't anyone sell me shares at .075?
Appears the bottom is in above my order.
Twitter: @AmarantusBio .... 9,840 followers
There's a Starbucks behind my local bar.
p.s. My 112,000 shares are looking good.
The rest of them are looking good also.
Congrats to the MNKD longs. Always good to see the shorts get burned.
Amarantus Appoints Robert Farrell, J.D. as Chief Financial Officer
SAN FRANCISCO, April 1, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to cell cycle dysregulation, endoplasmic reticulum stress, neurodegeneration and apoptosis, today announced the appointment of Mr. Robert Farrell, J.D. as Chief Financial Officer. Mr. Farrell brings over 20 years of healthcare, public company and CFO experience to Amarantus. Mr. Marc Faerber will continue with Amarantus in his new role as Corporate Controller and Vice President of Financial Operations.
"Amarantus is very well positioned to generate significant shareholder value through the further development and commercialization of its key assets in the months and years ahead," said Mr. Farrell, Amarantus' newly appointed Chief Financial Officer. "I am pleased to be joining now at this critical juncture as the Company prepares to uplist its common shares to a national stock exchange in 2014 as we commercialize LymPro, initiate a Phase 2B clinical trial for Eltoprazine in Parkinson's disease and prepare the MANF Program for an orphan drug designation submission. We expect 2014 to be a transformative year for Amarantus as we lay the groundwork for long-term shareholder value creation."
http://finance.yahoo.com/news/amarantus-appoints-robert-farrell-j-100000331.html
Twitter: @AmarantusBio .... 9,815 followers